iSpecimen Inc. (ISPC)
ISPC trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.08
0.00% on the day
Market cap
$2.7M
Nano cap
Revenue · 2025
$1.9M
-79.2% on 2024
Net income · 2025
-$10.5M
-543.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ISPC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001558569 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.9M |
| Net income | -$10.5M |
| Operating income | -$9.0M |
| Net margin | -543.7% |
| Operating margin | -465.4% |
| Revenue growth | -79.2% |
| Cash | $6.9M |
| Total assets | $9.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2026-08-07 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-04-01 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-09 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-09-14 |
Source: SEC EDGAR submissions feed, 329 recent filings. All filings on EDGAR.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BIAF | bioAffinity Technologies Inc. | $3.63 | -7.05% | $4.7M |
| ONMD | OneMedNet Corp | $4.02 | +2.29% | $24.2M |
| MXCT | MaxCyte Inc. | $0.9643 | -3.08% | $99.5M |
| NRC | NRC Health | $20.17 | -1.18% | $446.2M |
| OABI | OmniAb Inc. | $4.70 | -1.47% | $683.3M |
| ABSI | Absci Corporation | $9.10 | -5.89% | $1.6B |
| ICLR | ICON plc | $164.34 | -0.04% | $12.6B |
| CRL | Charles River Laboratories International Inc. | $299.02 | -0.94% | $14.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier